A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson, the drug is a nasal spray designed to treat severe forms of depression that don't respond to other medications.

This is when a patient has tried multiple forms of treatment for major depression—usually at least ... The drug is provided as a single-use nasal spray. This application means it's absorbed ...

It is the first new medicine to treat depression funded by the Australian government in over 30 years. Image: iStock Esketamine nasal spray will soon be subsidised under the Pharmaceutical ...

This is when a patient has tried multiple forms of treatment for major depression – usually at ... The drug is provided as a single-use nasal spray . This application means it's absorbed ...

This is when a patient has tried multiple forms of treatment for major depression – usually at ... The drug is provided as a single-use nasal spray. This application means it’s absorbed ...